GoodRx’s Provider Mode is a new experience built specifically for HCPs to help them access solutions for the medications they prescribe
BioTek reMEDys announced the addition of UPLIZNA to its specialty therapeutics portfolio to provide treatment to a broader patient population and further expand upon its diverse pharmaceutical product offering
The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced that the FDA approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS). PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven […]
Employer Perspectives Specialty Drug Step-Therapy Program Evaluation American Health and Drug Benefits, September 2016 Vol 9, No 6 – Industry Trends Matthew Harman, PharmD, MPH, Director, Clinical Pharmacy Strategies Employers Health, Columbus, OH F. Randy Vogenberg, PhD, RPh, Strategic Advisor and Co–Project Leader, Midwest Business Group on Health National Employer Biologics & Specialty Drug Initiative […]
New oral therapies Biogen Idec’s dimethyl fumarate is one of the new market entrants driving the shift to oral therapy growth in MS treatment, according to John Santilli of Access Market Intelligence, which provides business information to the pharmaceutical and healthcare industries. “Although this is Tecfidera’s first incident tied to PML use in more than 100,000 […]